Just when you thought Mylan's (MYL) - Get Viatris, Inc. Report EpiPen controversy had subsided, it resurfaces. The company's half-price version of its life-saving allergy treatment will be available by the end of this year, potentially months later than a timeline Mylan gave in August, according to Bloomberg. The cheaper version of the EpiPen shot will cost $300. Mylan spokeswoman Nina Devlin told Bloomberg that Mylan expected the so-called authorized generic EpiPen this year, "once we have assured that sufficient inventory will be available to meet anticipated orders."
Employees of TheStreet are restricted from trading individual securities.